Join us on at Alderley Park on 5 July 2022 for our next OBN BioTuesday event:
Kindly hosted by Alderley Park, the UK's largest single site life science campus and an accelerator for the translation of emerging cancer research in the UK, this event will shine a spotlight on some of the most innovative companies working within oncology in the North West region of the UK.
Our industry experts include:
Kath Mackay, Director of Life Sciences, Bruntwood SciTech, who is instrumental in developing Bruntwood SciTech's life sciences vision and strategy, supporting its UK expansion, championing innovation and investment in high value sector R&D.
Oliver Schon, VP Product Development & CMC at BiVictriX Therapeutics, an emerging drug discovery and development company generating a pioneering new class of next-generation anti-cancer therapeutics which exhibit superior selectivity towards the cancer.
Andy Yates, Senior VP and Chief Scientific Officer at Artelo Bio, a biopharmaceutical company dedicated to applying true biopharma discipline in leveraging past research and leading-edge, world-class science to accelerate the development and commercialization of a diverse portfolio of novel, endocannabinoid system modulating therapeutics.
Joely Irlam-Jones, Research Associate at University of Manchester, and CEO of ManTRa Diagnostics, a diagnostics development company originating from the Translational Radiobiology group, led by Professor Catharine West, and based within the Manchester Cancer Research Centre (MCRC) part of the University of Manchester.
Glen Clack, Chief Medical Officer at Evgen Pharma, a clinical drug development company developing sulforaphane-based medicines focussed on the treatment of cancer and inflammation.
Veronica Gray, Business Development Manager at Curileum Discovery, a biotechnology company in London that focuses on intervening early in the development of serious gastrointestinal diseases. We discover novel therapeutics to correct cell production in the continuously regenerating mucosal barrier of the gut.
Caroline Phillips, Head of Oncology, RedX Pharma, an AIM listed biotech company focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic disease.
Oncology specialist from Sygnature Discovery, which prides itself on offering a unique, high-quality, distinctive and tailored integrated drug discovery service to their clients.
18.00 Delegate registration, tea & coffee served
18.30 Welcome & Introductory keynote by Bruntwood SciTech
18.45 Keynote presentation
19.00 Company showcases
20.15 Audience Q&A
20.30 Drinks & networking
21.30 Event close
About Alderley Park:
Alderley Park is a place where world leading science, innovation and stylish living come together to create a place like no other. Part of Bruntwood SciTech, a 50:50 joint venture between leading property company Bruntwood and Legal and General, Alderley Park is currently undergoing £247m investment.
Home to the internationally-recognised Mereside bioscience campus, the Park offers more than 1m sq ft of high specification lab space, a range of scientific services and an accelerator delivering a comprehensive programme of business support for start-ups and scale-ups. It is also home to a vibrant and fast growing community of over 60 established and 150 pre-start up companies.
This is a place where people can live connected lives, in a community that will shape its own future. A place to do science, do business, work and live differently, with no boundaries.